Experts discuss the challenges of using surrogate endpoints in cancer screening

Experts discussed the potential role and challenges of surrogate endpoints in cancer screening in a webinar hosted by Cancer Research UK and Consilium Scientific.
Samantha Harrison leads 2 teams in the Policy, Information and Communications Directorate at Cancer Research UK, the Strategic Evidence team and the International Cancer Benchmarking and Partnership (ICBP) team. The Strategic Evidence team acts as a cancer evidence hub, and also focuses on horizon scanning and the impact assessment of cancer innovations. Sam has worked within the ICBP team for over 12 years, and now heads up the programme management and in-house ICBP team based at CRUK. ICBP is a global research and policy partnership, aiming to benchmark, and crucially assess, why cancer survival variation exists between similar high-income countries. The partnership has delivered more than 70 peer-reviewed publications.
Experts discussed the potential role and challenges of surrogate endpoints in cancer screening in a webinar hosted by Cancer Research UK and Consilium Scientific.
The UK National Screening Committee (UK NSC) advises ministers and the NHS in the 4 UK countries about all aspects of population screening and supports implementation of
screening programmes.